Therapeutic Momentum: Bench to Bedside Chats Titelbild

Therapeutic Momentum: Bench to Bedside Chats

Therapeutic Momentum: Bench to Bedside Chats

Von: Therapeutic Momentum
Jetzt kostenlos hören, ohne Abo

ZEITLICH BEGRENZTES ANGEBOT. Nur 0,99 € pro Monat für die ersten 3 Monate. 3 Monate für 0,99 €/Monat, danach 9,95 €/Monat. Bedingungen gelten. Jetzt starten.

Über diesen Titel

 Podcast by Therapeutic MomentumAll rights reserved Wissenschaft
Folgen
  • Andy Plump - Translational Roles & Global Perspectives

    Andy Plump - Translational Roles & Global Perspectives
    Mar 28 2025
    Andy Plump discusses his journey from a postdoc at UCSF to a leading roles in pharmaceutical research. Andy, who joined Merck in 2001, worked in clinical pharmacology. He highlighted the importance of genetics in target selection and shares his experiences at Sanofi and Takeda, emphasizing the cultural sensitivities and leadership lessons gained from global experiences. The interview explores the transformative potential of AI and machine learning in biopharmaceutical research. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.
    Mehr anzeigen Weniger anzeigen
    45 Min.
  • Mathai Mammen - Motivated by Math, Medicine & Memories

    Mathai Mammen - Motivated by Math, Medicine & Memories
    Mar 28 2025
    Mathai Mammen is a world-renowned innovator in drug discovery, development, and team- and company-building responsible for creating 13 transformational medicines from discovery through commercial launch and more than 25 other potential medicines that have achieved clinical proof-of-concept, many of these practice-changing. Mathai is the CEO, President and Chairman of Cambridge-based Parabilis Medicines, a clinical-stage biopharmaceutical company advancing a new category of peptide therapeutics for people affected by cancer and other severe diseases. Previously Mathai was Executive Vice President of Pharmaceuticals, R&D at Johnson & Johnson, one of the largest R&D organizations in the world. Prior to that Mathai was the leader of much of the research at Merck including Oncology, Immunology and Cardiovascular Disease. He began his career as head of R&D at Theravance, Inc., a company he co-founded out of graduate school based on his work at Harvard University with Dr. George Whitesides, which split to form Theravance Biopharma and Innoviva. Mathai holds an M.D. from the Harvard Medical School and Massachusetts Institute of Technology (HST) and a Ph.D. in chemistry from Harvard University.
    Mehr anzeigen Weniger anzeigen
    1 Std. und 8 Min.
  • Kate Bingham: Ventures & Vision

    Kate Bingham: Ventures & Vision
    Mar 1 2025
    Dame Catherine Elizabeth "Kate" Bingham is a British biochemist and life‑sciences venture capitalist with a unique combination of skills and high impact roles. Since 1991, she has been a managing partner at SV Health Investors, co‑founding the Dementia Discovery Fund and helping launch multiple first‑in‑class drugs. In May 2020, she chaired the UK’s Vaccine Taskforce, securing 350 million COVID‑19 doses and leading the country to be the first Western nation to begin vaccinations
    Mehr anzeigen Weniger anzeigen
    44 Min.
Noch keine Rezensionen vorhanden